Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor

Thrombosis and Haemostasis

Volumn 88, Issue 6, 2002, Pages 898-899

  Hansen, Ryan J ^a   Balthasar, Joseph P ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

FcRn; Immune thrombocytopenia; Intravenous immunoglobulin; Pharmacokinetics

Indexed keywords

ABCIXIMAB; FC RECEPTOR; IMMUNOGLOBULIN; NEONATAL FC RECEPTOR; THROMBOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG CLEARANCE; DRUG EFFECT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA;

EID: 0036918050     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613331     Document Type: Article

References (16)

1. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40.
2. Knapp MJ, Colburn PA. Clinical uses of intravenous immune globulin. Clin Pharm 1990; 9: 509-29.
3. Krause I, Bank M, Kopolovic J, et al. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol 1995; 22: 1068-74.
4. Hansen RJ, Balthasar JP. Intravenous immunoglobulin effects on platelet count and anti-platelet antibody disposition in a rat model of immune thrombocytopenia. Blood 2002; 100: 2087-93.
5. Bleeker WK, Teeling JL, Hack CE. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: Studies in experimental models to determine the magnitude and time course of the effect. Blood 2001; 98: 3136-42.
6. Pierangeli SS, Espinola R, Liu X, Harris EN, Salmon JE. Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype. Rheum Arthritis 2001; 44: 876-83.
7. Sater RA, Rostami A. Treatment of Guillain-Barre syndrome with intravenous immunoglobulin. Neurology 1998; 51: S9-15.
8. Masson PL. Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg. J Autoimmun 1993; 6: 683-9.
9. Yu Z. Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227-8.
10. Telleman P, Junghans RP. The role of the Brambell receptor (FcRB) in liver: Protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile. Immunology 2001; 100: 245-51.
11. Hansen RJ, Balthasar JP. Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: A quantitative rat model of immune thrombocytopenic purpura. J Pharm Exp Ther 2001; 298: 1-7.
12. Brambell F, Hemmings W, Morris I. A theoretical model of gamma-globulin catabolism. Nature 1964; 203: 1352-5.
13. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 1996; 26: 690-6.
14. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 1996; 93: 5512-6.
15. Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE. Increased clearance of IgG in mice that lack beta 2-microglobulin: Possible protective role of FcRn. Immunology 1996; 89: 873-8.
16. Ghetie V, Ward ES. FcRn: The MHC class I-related receptor that is more than an IgG transporter. Immunol Today 1997; 18: 592-8.